159 related articles for article (PubMed ID: 15041404)
1. FTY720 immunomodulation: optimism for improved transplant regimens.
Ferguson R
Transplant Proc; 2004 Mar; 36(2 Suppl):549S-553S. PubMed ID: 15041404
[TBL] [Abstract][Full Text] [Related]
2. FTY720: early clinical experience.
Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
[TBL] [Abstract][Full Text] [Related]
3. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
5. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Koshiba T; Van Damme B; Rutgeerts O; Waer M; Pirenne J
Transplantation; 2003 Apr; 75(7):945-52. PubMed ID: 12698078
[TBL] [Abstract][Full Text] [Related]
6. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
Tedesco-Silva H; Lorber MI; Foster CE; Sollinger HW; Mendez R; Carvalho DB; Shapiro R; Rajagopalan PR; Mayer H; Slade J; Kahan BD;
Clin Transplant; 2009; 23(5):589-99. PubMed ID: 19719728
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
8. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
9. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
Westhoff TH; Schmidt S; Glander P; Liefeld L; Martini S; Offermann G; Neumayer HH; Zidek W; van der Giet M; Budde K
Nephrol Dial Transplant; 2007 Aug; 22(8):2354-8. PubMed ID: 17526535
[TBL] [Abstract][Full Text] [Related]
10. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
Tedesco-Silva H; Pescovitz MD; Cibrik D; Rees MA; Mulgaonkar S; Kahan BD; Gugliuzza KK; Rajagopalan PR; Esmeraldo Rde M; Lord H; Salvadori M; Slade JM;
Transplantation; 2006 Dec; 82(12):1689-97. PubMed ID: 17198261
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.
Maeda A; Goto M; Zhang J; Bennet W; Groth CG; Korsgren O; Wennberg L
Transplantation; 2003 Apr; 75(8):1409-14. PubMed ID: 12717240
[TBL] [Abstract][Full Text] [Related]
13. FTY720--the first compound of a new promising class of immunosuppressive drugs.
Kunzendorf U; Ziegler E; Kabelitz D
Nephrol Dial Transplant; 2004 Jul; 19(7):1677-81. PubMed ID: 15199193
[No Abstract] [Full Text] [Related]
14. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Suzuki T; Jin MB; Shimamura T; Yamashita K; Taniguchi M; Nomura M; Yokota R; Fukai M; Magata S; Horiuchi H; Fujita M; Nagashima K; Furukawa H; Todo S
Transpl Int; 2004 Nov; 17(10):574-84. PubMed ID: 15592714
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
16. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Sakagawa T; Kiyochi H; Honda K; Kobayashi N
Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
[TBL] [Abstract][Full Text] [Related]
17. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice.
Lopes CT; Gallo AP; Palma PV; Cury PM; Bueno V
Transplant Proc; 2008 Apr; 40(3):856-60. PubMed ID: 18455036
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
19. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
Transplantation; 2005 Jun; 79(11):1553-60. PubMed ID: 15940045
[TBL] [Abstract][Full Text] [Related]
20. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.
Tedesco-Silva H; Szakaly P; Shoker A; Sommerer C; Yoshimura N; Schena FP; Cremer M; Hmissi A; Mayer H; Lang P;
Transplantation; 2007 Oct; 84(7):885-92. PubMed ID: 17984842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
